Condition

Interstitial lung disease and pulmonary sarcoidosis

Clinical trials and treatment information for Interstitial lung disease and pulmonary sarcoidosis

4.3M

People Affected

150

Active Trials

86K

New Cases/Year

188K

Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

Prednisone

75% Effectiveness• 90% Confidence• 50% Safety• 8 trials• 2M participants

HIGH EvidenceExcellent ValueDose: 20-40 mg daily, tapered

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

Days to 2 weeks

Duration

Months to years

Response Rate

75%

Remission Rate

40%

Common Side Effects:

Weight gain: 80%

Mood changes: 50%

Insomnia: 40%

Hyperglycemia: 30%

Increased infection risk: 20%

Osteoporosis (long-term): 15%

Annual Cost of Care

Drug Cost

$150

Monitoring

$750

Side Effects

$1,200

Total Annual

$2,100

Cost-Effectiveness

EXCELLENT

Cost per Remission

$5,250

Cost per Responder

$2,800

Treatment Outcomes

Primary Outcomes

Forced Vital Capacity (FVC)65% of predicted

+10% (increase by 6.5 percentage points of predicted)

6-Minute Walk Distance (6MWD)320 meters

+12.5% (+40 meters)

Dyspnea Severity (mMRC score)mMRC score: 3/4

-33.3% (-1 point)

Secondary Benefits

Cough Severity (VAS)65 mm (on 100 mm VAS)

-23.1% (-15 mm)

Quality of Life (SGRQ total score)SGRQ total score: 48/100

-10.4% (-5 points)

C-reactive Protein (CRP)15 mg/L

-66.7% (-10 mg/L)

Common Side Effects

Weight gain

+80%

Mood changes

+50%

Insomnia

+40%

Clinical Trial Phases:

Phase 4

Pirfenidone

65% Effectiveness• 85% Confidence• 40% Safety• 1 trials• 2.5K participants

HIGH EvidencePoor ValueDose: 2403 mg daily

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

3-6 months (sustained effect)

Duration

Lifetime

Response Rate

55%

Remission Rate

Number Needed to Treat (NNT)

Common Side Effects:

Nausea: 35%

Diarrhea: 25%

Photosensitivity: 15%

Rash: 15%

Liver enzyme elevation: 10%

Annual Cost of Care

Drug Cost

$7,500

Monitoring

$1,500

Side Effects

$1,000

Total Annual

$10,000

Cost-Effectiveness

POOR

QALYs Gained

0.2

ICER

$250,000/QALY

Cost per Responder

$18,182

Treatment Outcomes

Primary Outcomes

Absolute Forced Vital Capacity (FVC)3000 mL

-5% (-150 mL (annual decline))

6-Minute Walk Test (6MWT) distance350 meters

-5.7% (-20 meters (annual decline))

UCSD Shortness of Breath Questionnaire (SOBQ) score25 points (0-60, higher is worse)

+10% (+2.5 points (annual increase, less than placebo))

Secondary Benefits

St. George's Respiratory Questionnaire (SGRQ) total score45 points (0-100, higher is worse)

+5.5% (+2.5 points (annual increase, less than placebo))

Diffusion Capacity (DLCO) % predicted50% of predicted

-5% (-2.5 percentage points (annual decline))

Common Side Effects

Nausea

+35%

Diarrhea

+25%

Photosensitivity

+15%

Clinical Trial Phases:

Phase 3Phase 4

Nintedanib

65% Effectiveness• 85% Confidence• 40% Safety• 1 trials• 3.5K participants

HIGH EvidencePoor ValueDose: 150 mg twice daily

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

3-6 months (sustained effect)

Duration

Lifetime

Response Rate

55%

Remission Rate

Number Needed to Treat (NNT)

Common Side Effects:

Diarrhea: 65%

Nausea: 25%

Vomiting: 10%

Liver enzyme elevation: 8%

Annual Cost of Care

Drug Cost

$7,500

Monitoring

$1,500

Side Effects

$1,000

Total Annual

$10,000

Cost-Effectiveness

POOR

QALYs Gained

0.2

ICER

$280,000/QALY

Cost per Responder

$18,182

Treatment Outcomes

Primary Outcomes

Forced Vital Capacity (FVC) decline2800 mL (typical for Idiopathic Pulmonary Fibrosis)

-4.28% (-120 mL over 52 weeks)

Forced Vital Capacity (FVC) decline (Progressive Fibrosing ILD)2700 mL (typical for other progressive fibrosing ILDs, including sarcoidosis)

-4.07% (-110 mL over 52 weeks)

Diffusion Capacity of the Lungs for Carbon Monoxide (DLCO) decline55% of predicted

-6.36% (-3.5% of predicted over 52 weeks)

Secondary Benefits

Annualized Rate of Acute Exacerbations0.2 events/patient-year

-50% (-0.1 events/patient-year over 52 weeks)

St. George's Respiratory Questionnaire (SGRQ) Total Score35 points (0-100 scale, higher is worse)

+10% (+3.5 points over 52 weeks)

6-Minute Walk Distance (6MWD)350 meters

-1.43% (-5 meters over 52 weeks)

Common Side Effects

Diarrhea

+65%

Nausea

+25%

Vomiting

+10%

Clinical Trial Phases:

Phase 3Phase 4

Infliximab

60% Effectiveness• 75% Confidence• 35% Safety• 30 trials• 800 participants

MODERATE EvidencePoor ValueDose: 5 mg/kg IV every 4-8 weeks

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

2-3 months

Duration

Long-term, potentially indefinite

Response Rate

60%

Remission Rate

15%

Common Side Effects:

Infusion reactions: 15%

Increased infection risk: 8%

Headache: 10%

Nausea: 5%

Annual Cost of Care

Drug Cost

$30,000

Monitoring

$3,000

Side Effects

$2,000

Total Annual

$35,000

Cost-Effectiveness

POOR

QALYs Gained

0.25

ICER

$200,000/QALY

Cost per Remission

$233,333

Cost per Responder

$58,333

Treatment Outcomes

Efficacy Outcomes

Overall Effectiveness

+60%

Response Rate

+60%

Remission Rate

+15%

Common Side Effects

Infusion reactions

+15%

Increased infection risk

+8%

Headache

+10%

Clinical Trial Phases:

Phase 3Phase 4

Methotrexate

58% Effectiveness• 80% Confidence• 30% Safety• 2 trials• 4K participants

MODERATE EvidenceExcellent ValueDose: 10-25 mg once weekly

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

2-3 months

Duration

1-2 years (or longer)

Response Rate

60%

Remission Rate

30%

Common Side Effects:

Nausea: 25%

Fatigue: 15%

Liver enzyme elevation: 15%

Oral ulcers: 8%

Myelosuppression (rare): 2%

Annual Cost of Care

Drug Cost

$200

Monitoring

$750

Side Effects

$300

Total Annual

$1,250

Cost-Effectiveness

EXCELLENT

Cost per Remission

$4,167

Cost per Responder

$2,083

Treatment Outcomes

Primary Outcomes

Forced Vital Capacity (FVC) % predicted65% predicted

+7.69% (+5 percentage points)

Dyspnea (mMRC scale)mMRC scale: 2/4

-50% (-1 point)

Corticosteroid DoseOral Prednisone: 10 mg/day

-50% (-5 mg/day)

Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) % predicted55% predicted

+5.45% (+3 percentage points)

Secondary Benefits

Fatigue (Fatigue Assessment Scale - FAS)FAS score: 30/50

-10% (-3 points)

Quality of Life (SF-36 Physical Component Summary)SF-36 PCS: 35/100

+10% (+3.5 points)

C-Reactive Protein (CRP)CRP: 8 mg/L

-25% (-2 mg/L)

Common Side Effects

Nausea

+25%

Fatigue

+15%

Liver enzyme elevation

+15%

Clinical Trial Phases:

Phase 4

Azathioprine

58% Effectiveness• 80% Confidence• 30% Safety• 1 trials• 3K participants

MODERATE EvidenceExcellent ValueDose: 1-2.5 mg/kg daily

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

3-6 months

Duration

1-2 years (or longer)

Response Rate

60%

Remission Rate

30%

Common Side Effects:

Nausea: 15%

Vomiting: 8%

Myelosuppression: 5%

Liver enzyme elevation: 8%

Increased infection risk: 10%

Annual Cost of Care

Drug Cost

$200

Monitoring

$750

Side Effects

$300

Total Annual

$1,250

Cost-Effectiveness

EXCELLENT

Cost per Remission

$4,167

Cost per Responder

$2,083

Treatment Outcomes

Primary Outcomes

Forced Vital Capacity (FVC)65% of predicted FVC

+4.6% (+3% points of predicted FVC)

Diffusion Capacity for Carbon Monoxide (DLCO)55% of predicted DLCO

+3.6% (+2% points of predicted DLCO)

Dyspnea (mMRC Scale)mMRC Dyspnea Scale: 2.5/4

-20% (-0.5 points)

Prednisone Equivalent Dose15 mg/day Prednisone equivalent

-33.3% (-5 mg/day Prednisone equivalent)

Secondary Benefits

St. George's Respiratory Questionnaire (SGRQ)SGRQ Score: 45/100

-13.3% (-6 points)

6-Minute Walk Distance (6MWD)400 meters

+6.25% (+25 meters)

Common Side Effects

Nausea

+15%

Vomiting

+8%

Myelosuppression

+5%

Clinical Trial Phases:

Phase 4